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Abstract
In contrast to normal differentiated cells that depend on mitochondrial oxidative phosphorylation for energy production,
cancer cells have evolved to utilize aerobic glycolysis (Warburg’s effect), with benefit of providing intermediates for biomass
production. MicroRNA-122 (miR-122) is highly expressed in normal liver tissue regulating a wide variety of biological
processes including cellular metabolism, but is reduced in hepatocellular carcinoma (HCC). Overexpression of miR-122 was
shown to inhibit cancer cell proliferation, metastasis, and increase chemosensitivity, but its functions in cancer metabolism
remains unknown. The present study aims to identify the miR-122 targeted genes and to investigate the associated
regulatory mechanisms in HCC metabolism. We found the ectopic overexpression of miR-122 affected metabolic activities
of HCC cells, evidenced by the reduced lactate production and increased oxygen consumption. Integrated gene expression
analysis in a cohort of 94 HCC tissues revealed miR-122 level tightly associated with a battery of glycolytic genes, in which
pyruvate kinase (PK) gene showed the strongest anti-correlation coefficient (Pearson r=20.6938, p=,0.0001). In addition,
reduced PK level was significantly associated with poor clinical outcomes of HCC patients. We found isoform M2 (PKM2) is
the dominant form highly expressed in HCC and is a direct target of miR-122, as overexpression of miR-122 reduced both
the mRNA and protein levels of PKM2, whereas PKM2 re-expression abrogated the miR-122-mediated glycolytic activities.
The present study demonstrated the regulatory role of miR-122 on PKM2 in HCC, having an implication of therapeutic
intervention targeting cancer metabolic pathways.
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Introduction
Hepatocellular carcinoma (HCC) is a common malignant
tumor. In 2008, there were over 700,000 new incidences
diagnosed worldwide [1]. HCC patients usually have poor clinical
outcome – only 5–9% of them survive five years or more. Surgical
resection, liver transplantation, and radiofrequency ablation may
provide cure for some early staged patients, but most patients are
unfortunately diagnosed at advanced stage given the asymptom-
atic nature of HCC. Moreover, HCC is highly resistant to
chemoregimens, thus many of the patients die from disease
recurrence. New therapeutic is in need. In recent years, miRNA
has emerged as an important class of gene regulator in HCC
development, and the investigation of its relevant regulatory
mechanisms might provide new targets for the therapeutic
intervention.
As regarded as a liver-specific non-coding RNA, miR-122 is
highly expressed in normal liver tissue, but its expression level
progressively reduced in cirrhotic and HCC tissues [2]. Recently, a
mouse model with germline deletion of miR-122a showed
promoting epithelial-mesenchymal transition (EMT) and sponta-
neous HCC formation [3]. In xenograft mouse models, miR-122
was demonstrated to affect HCC intrahepatic metastasis by
angiogenesis suppression [4]. Restoration of miR-122 in HCC
cells could suppress tumorigenic phenotypes, such as cell
proliferation, migration, invasion, and anchorage-independent
growth [5]. Recently, molecular profiling of human HCC tumors
at gene and protein levels have shed light on the relationship
between miR-122 and liver metabolism [2,6]. These studies have
shown that the networks of genes/proteins that correlated with
miR-122 expression were enriched for functions associated with
metabolic processes. Notably, mice knockout of miR-122 devel-
oped HCC with extensive lipid accumulation and reduced
glycogen storage [3], implying the tumor suppressive role of
miR-122 via modulating cancer metabolism.
Alteration of glycolytic metabolism is a common feature of
cancer cells. Contrary to normal differentiated cells that use
mitochondrial oxidative phosphorylation as a main source for
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energy production, cancer cell is addictively dependent on
glycolysis – a phenomenon firstly reported by Otto Warburg
who observed that tumor cells showed high glycolytic rate with
production of lactate even in an oxygen-rich condition [7]. The
phenomenon was coined as Warburg effect or aerobic glycolysis.
This shift in metabolism is believed to provide metabolic needs for
the rapid proliferating cancer cells to grow, rather than energy
production [8]. The understanding of the control of this metabolic
shift is pivotal to identify potential targets for cancer therapeutics,
and the present study is to identify and characterize the miR-122-
targeted metabolic genes with an attempt to evaluate the potential
of reversing aerobic glycolysis in HCC.
Materials and Methods
Clinical specimens and cell culture
Human HCC clinical samples were collected from patients who
had hepatectomy for treatment of HCC at Queen Mary Hospital,
Pokfulam, Hong Kong. Clinicopathologic features are summa-
rized in Table 1 and elsewhere [2]. Liver cancer cell lines (HepG2,
Hep3B, Huh-7, H2P, H2M, MHCC97L, and MHCC97H) were
obtained as previously described [9,10]. Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(Invitrogen) at 37uC in a 5% CO2 incubator.
RNA isolation, microarray analysis, and real-time
quantitative PCR
Total RNA was extracted from cells and human HCC tumor
samples using Trizol (Invitrogen), followed by reverse transcription
[2]. MiRNA profiling was performed as previously described [2].
Real-time quantitative PCR (qPCR) detection of genes in cell lines
was performed using 2X Power SYBR Green Master Mix
(Applied Biosystems, Foster City, CA) according to manufacturer’s
instructions. Detection of miR-122 in cell lines was performed
using TaqMan microRNA assays according to manufacturer’s
instructions (Part number: 4427975, Applied Biosystems). Tran-
scriptional expressions of PKM1, PKM2 and miR-122 were
referenced to 18S housekeeping gene. Experiments were conduct-
ed in duplicates in three independent assays.
Western blotting
Western blot analysis was performed as described previously
[11]. The membranes were blotted with antibodies of PKM2 (Cell
signaling Inc., Beverly, MA), or b-actin (Sigma-Aldrich, Saint
Louis, MO).
Immunohistochemistry
Paraffin-embedded tissue blocks were sectioned for immuno-
histochemical staining. After antigen retrieval and peroxidase
blocking, the sections were incubated with human PKM2
antibody (Cell signaling Inc.) in 1:600. The rest of the steps were
performed as described [12].
Construction of expression vectors
The miR-122 expression vector (pc-miR-122) was constructed
as previously described [11]. The PKM2 expression vector was
constructed by PCR amplification of the entire coding region of
PKM2, but lacked the 59- and 39-UTR region. The amplified
fragment was cloned into pcDNA3.1 using NotI and EcoRI. The
expression vector was subsequently verified by DNA sequencing,
and was called pc-PKM2 hereafter. The miR-122 inhibitor (hsa-
miR-122-5p, Catalog # 4464084 ), siRNA targeting PKM2
(siPKM2, Catalog # AM51331) and non-targeting siRNA
(Silencer Negative control #1 siRNA, siCtrl) were purchased
from Invitorgen.
Lactate assay
Cells were seeded onto a 6-well plate. For each well, 4 mg of
pcDNA3.1 or pc-miR-122 was transfected using 5 ml of Lipofec-
tamine 2000 (Invitrogen) according to manufacturer’s instruction.
Medium was changed 24-hour post-transfection. Lactate assay
(BioVision, Mountain View, CA) was then performed to quantify
the cellular lactate level at 48-hour post-transfection, according to
manufacturer’s instructions. The plate was read at OD570, and
the amount of lactate was expressed as nmol/16106 cells.
Table 1. Clinical correlation between PK transcriptional
expression and clinicopathological parameters of HCC
patients (n = 217).
Variables Frequency (%) PK expression P values
, median $ median
Sex
Male 171 (78.8) 89 82 0.302
Female 46 (21.2) 20 26
Age
, 55 111 (51.2) 57 54 0.735
$ 55 106 (48.8) 52 54
Tumor size, cm
, 5 86 (39.6) 46 40 0.437
$ 5 131 (60.4) 63 68
Alpha fetoprotein,
ng/mL
, 100 108 (49.8) 65 43 0.004
$ 100 109 (50.5) 44 65
HBsAg
Negative 30 (13.8) 17 13 0.448
Positive 187 (86.2) 92 95
1Histological
differentiation
Well 37(19.4) 25 12 0.033
Moderate/Poor 154 (80.6) 74 80
TNM stage
Early (I, II) 98 (45.2) 60 38 0.003
Late (III, IV) 119 (54.8) 49 70
Cirrhosis
Negative 90 (41.5) 47 43 0.621
Positive 127 (58.5) 62 65
Venous infiltration
Absent 107 (49.5) 65 42 0.002
Present 109 (50.5) 43 66
Recurrence
Absent 90 (41.5) 49 41 0.296
Present 127 (58.5) 60 67
1Analysis on 191 patients.
doi:10.1371/journal.pone.0086872.t001
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Cell viability assay
Cells were seeded onto 6-well plate, and transfection was
performed on the next day as mentioned above. At 24-hour post-
transfection, cells were trypsinized and seeded onto 96-well plates
at a density of 5,000 cells/well. At 48-hour post-transfection, the
plates were subjected to different culturing conditions: normoxia,
hypoxic chamber with 1% oxygen, addition of 100 uM desfer-
rioxamine (DFO), or addition of 200 ng/ml Oligomycin (Sigma-
Alrich). At 72-hr post-transfection, a MTT assay was performed to
measure cell viability.
Oxygen consumption assay
We used MitoXpress-Xtras HS (Luxcel Biosciences, Cork,
Ireland) to quantify the oxygen consumption of the transfected
HepG2. The assay was based on the phosphorescent oxygen
sensitive probe that is quenched by O2 at the excited state. At 48-
hr post-transfection, MitoXpress probe was added to each well of
the 96-well plate and the signals were measured according to the
manufacturer’s instructions. The fluorescence-time profiles of
different treatments were linearized using the following coordinate
scale [Y: I(t0)/(I(t) –I(t0)); X: 1/t (min
21)], in which I(t0) represents
fluorescence intensity at the start, and I(t) represents the intensity
at time t of monitoring. Linear regression was applied to each
transformed profile and the slope represents the oxygen consump-
tion rate.
Statistical analyses
A Student t-test was performed to compare two groups, and p#
0.05 was considered significant. Kaplan-Meier plots and log-rank
tests were used for survival analysis.
Ethics statement
The study protocol was approved by the Internal Review Board
of the Joint Ethics Committee of The University of Hong Kong
Figure 1. miR-122 expression resulted in reduced aerobic glycolysis of HCC cells. (A) Expression of miR-122 detected by qPCR 48-hour
post-transfection in HepG2 or MHCC97H cells. Mock: transfection reagent only; Ctrl: transfection with empty-vector; miR-122: transfection with pc-
miR-122. (B) Lactate contents of miR-122 or Ctrl treated cells. (C) Oxygen consumption rate of miR-122 or Ctrl treated cells. (D) Cell viability of miR-
122 or Ctrl treated cells under different culturing conditions: normoxia (21% oxygen), 100 uM desferrioxamine (DFO), hypoxia (1% oxygen), or 100 ng/
ml of oligomycin. * p,0.05, ** p,0.01, compared to respective Ctrl. Error bars represent S.E.M.
doi:10.1371/journal.pone.0086872.g001
miR-122 Affects HCC Metabolism through PKM2
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e86872
and the Queen Mary Hospital (Pokfulam, Hong Kong), and all
HCC patients have given written informed consents on the use of
clinical specimens for medical research.
Results
miR-122-mediated reversal of aerobic glycolysis in HCC
cells
To evaluate the potential of miR-122 reversing aerobic
glycolysis, we conducted lactate production and oxygen consump-
tion assays in HepG2 and MHCC97H cells (with low endogenous
miR-122 level) transfected with miR-122 construct or vector
control. The miR-122 transfectants gave, as determined by real-
time qPCR, a boost of a 4–5 folds increase of miR-122 level as
compared to the vector (Fig. 1A), whereas the lactate production
was reduced (Fig. 1B) and oxygen consumption in HepG2 cells
was increased (Fig. 1C), indicating a metabolic shift from glycolysis
to oxidative phosphorylation.
We next investigated the tumor suppressive phenotype (cell
viability assay) in the miR-122 transfectants with respect to
oxidative phosphorylation under different culturing conditions.
We found the miR-122 transfectants had reduced cell viability
under normoxia (Fig 1D), confirming observation from others [5],
and interestingly, further reduction in cell viability of miR-122
transfectants was observed under hypoxia (1% oxygen), by
addition of DFO or oligomycin (Fig. 1D). Oligomycin is a specific
inhibitor of mitochondrial ATP synthase, and DFO is an iron
chelator that is commonly used to induce the effects of hypoxia.
Compared to the normoxia environment, cells grown under the
above-mentioned three conditions had compromised oxidative
phosphorylation. The further reduction of cell viability in these
conditions suggests miR-122 cells were more dependent on
oxidative phosphorylation to support cell growth. Together, the
present findings supported the role of miR-122 on reversing the
aerobic glycolysis to normal physiologic oxidative phosphorylation
in HCC cells.
Pyruvate kinase (PK) is anti-correlated with miR-122
expression and associated with clinical outcome
Since miR-122 reduced aerobic glycolysis of HCC cells, we
asked which of the genes are involved in this metabolic alteration.
Figure 2. PK is anti-correlated with miR-122 expression in HCC tumors and correlates with outcome of HCC patients. (A)
Transcriptional expression correlation of PK and miR-122 in 94 human HCC tumor samples. (B) Kaplan-Meier overall survival (left panel) and disease-
free survival (right panel) analyses of 217 HCC patients, based on PK transcript level. Patients were divided into two groups: 1) higher than the median
PK expression level, 2) lower than the median PK expression level.
doi:10.1371/journal.pone.0086872.g002
Table 2. PKM2 expression in 12 HCC tumor tissue.
PKM2 Stage I-II Stage III-IV Total
– 2 1 3
+/++ 4 5 9
Total 6 6 12
doi:10.1371/journal.pone.0086872.t002
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To search for such targets, we analyzed the expression profiles of
glycolytic genes that are anti-correlated with the miR-122 level in
a cohort of 94 HCC samples (GEO accession number GSE22058).
The findings revealed the following target genes with predicted
miR-122 binding site at the 3’UTR region: PK, ALDOA, GNPDA1,
PFKFB2, and AKR1B10, in which the PK gene has the highest anti-
correlation coefficient with miR-122 (Pearson r=–0.6938,
p=,0.0001) (Fig. 2A). Next we tested whether these genes were
relevant to the clinical outcome of HCC patients. Among these
anti-correlated glycolytic genes, the PK transcript level was
significantly associated with the overall survival time of HCC
patients (Fig. 2B), as well as the serum alpha-fetoprotein level,
histological differentiation of tumor tissue, and TNM stage (Table
1).
PKM2 is highly expressed in HCC cell lines and clinical
samples
The PK gene has two splice variants in humans: M1 and M2.
Both isoforms entail the same 3’UTR sequence, and therefore the
same miR-122 binding site. The miRNA target prediction tool,
TargetScan 5.1, showed that miR-122 is the only miRNA species
that binds to the 3’UTR of PK gene (Fig. 3A). Interestingly, the M2
variant (PKM2) was the dominant form in HCC cell lines whereas
the expression of M1 variant (PKM1) was minimal (Fig. 3B),
suggesting PKM2 is the tumorigenic form and highly expressed in
tumors in agreement with a previous study [13]. Among the HCC
cell lines tested, PKM2 generally exhibited higher expression levels
in the metastatic cell lines than the primary HCC cell lines. In
addition, the negative correlation in expression between PKM2
and miR-122 was recapitulated in a panel of HCC cell lines, with
the Pearson r value of –0.7074 (p=0.0377) (Fig. 3C), similar to that
observed in the clinical samples. Further confirmation of PKM2
protein expression in HCC tumors was conducted with PKM2
specific monoclonal antibody by immunohistochemical staining.
Among the 12 pairs of tumor and non-tumor tissues tested, 5
tumor samples were scored at strong (++) expression, 4 samples at
moderate (+), and 3 samples at minimal/undetectable (–) levels for
PKM2 (Fig. 3D, Table 2). The following study focused on the
oncogenic functions of PKM2 variant in HCC.
miR-122 targets PKM2 and regulates its expression
To validate PKM2 as a direct target of miR-122, we transfected
miR-122 expression vector into HCC cells, and found the PKM2
mRNA level was significantly reduced in the miR-122 cells,
compared to the controls (Fig. 3E). The endogenous protein level
of PKM2 was also decreased upon ectopic expression of miR-122
(Fig. 3F). In accordance with this observation, silencing miR-122
expression by using miR-122 inhibitor upregulated the protein
and mRNA levels of PKM2 in HepG2 cells (Fig. 3E-F). In
addition, in our pervious mass screening of potential miR-122
targets using luciferase assay, we found the activity of a luciferase
construct bearing 3’UTR of PKM2 was significantly reduced upon
expression of miR-122 [6]. Collectively, the data showed that
PKM2 is a direct target of miR-122.
miR-122 regulates PKM2 mediated metabolism
To confirm PKM2 is involved in miR-122 regulated metabolic
process, we examined whether the reduction of PKM2 lowers
lactate production resembling the effect of miR-122 overexpres-
sion. We first assessed the suppression efficiency of siPKM2 RNAi
duplex. As shown by real-time qPCR data, the siPKM2 gave a
41% reduction on PKM2 expression (Fig. 4A) that is similar to the
effect of miR-122 overexpression in HepG2. Similar results were
observed in siPKM2 transfected MHCC97H cells. Next, we
transfected the two cell lineswith either siPKM2 or siCtrl, and
performed a lactate assay at 48 hours. A significant reduction of
lactate production was observed with the siPKM2 but not with the
control (Fig. 4B).
On the other hand, PKM2 could counteract the effect of miR-
122 on lactate production. HepG2 cells were co-transfected with
both the miR-122 and the PKM2 decoy (the plasmid expressed
the entire PKM2 coding region but lacked the 3’UTR, i.e. no miR-
122 binding site),and MHCC97H cells were co-transfected with
both siPKM2 and miR-122 inhibitor. Our data showed overex-
pression of PKM2 decoy obviously abrogated the miR-122
suppression effect on lactate production, while silencing endoge-
nous miR-122expression reversed the effect of siPKM2 on lactate
production (Fig. 4C and 4D), supporting the miR-122 and PKM2
regulatory relationship on cancer metabolism.
Discussion
MiR-122 plays an important role in maintenance of normal
physiological metabolism in the liver. Dys- or down-regulation of
miR-122 is frequently implicated in development of cirrhosis and
liver cancer and tumor metastasis [3,4,14] as spontaneous liver
tumors were observed in Mir122a–/– mice, whereas reduced
disease manifestation and tumor incidence when miR-122
expression were restored. In our previous study, we did not found
significant correlation of miR-122 with overall survival and
disease-free survival rates, although there was a tendency.
However, miR-122-targeted genes that are enriched in metabolic
pathways significantly associated with HCC survival rates [2]. The
connection between PKM2 and miR-122 was observed during
differentiation process of human embryonic stem cell (hESCs) into
hepatocytes [15]. Furthermore, overexpressing miR-122 leads to
hESCs and HCC cells self-renewal and proliferation deficiency
[15]. The present study provides new evidences that miR-122
targets PKM2 metabolic enzyme which plays a pivotal role in
aerobic glycolysis having significant association with poor clinical
outcomes of the HCC patients. We also demonstrated the strong
anti-correlation of miR-122 and PKM2 expression levels in the
cohort of 94 HCC samples. Targeted delivery of miR-122 into
HCC may have potential therapeutic values by reversing aerobic
Figure 3. PKM2 is a direct target of miR-122. (A) Predicted binding interaction between 3’UTR of PK and miR-122. (B) Expressions of PKM1 and
PKM2 in HCC cell lines, as detected by qPCR method. (C) Expression correlation of PKM2 and miR-122 in a panel of HCC cell lines. (D)
Immunohistochemical staining of anti-PKM2 antibody in paired tumor and adjacent nontumor tissue. A total of 12 tumor/nontumor tissue pairs were
tested, and representative photomicrographs are shown. (E) Expression level of PKM2 mRNA and miR-122 levels in Ctrl, miR-122, siCtrl or miR-122
inhibitor treated HepG2 cells. Mock: transfection reagent only; Ctrl: transfection with empty-vector; miR-122: transfection with pc-miR-122; siCtrl:
transfection with non-targeting siRNA; miR-122 inhibitor: transfection with miR-122 inhibitor. Data were derived from three independent
experiments. (F) Immunoblots (upper panel) of protein level of PKM2 after transfection of miR-122 or miR-122 inhibitor in HepG2 cells. The intensities
are quantified and represented in the graph in lower panel. Data were derived from two independent experiments. *p,0.05, **p,0.01, Error bars
represent S.E.M.
doi:10.1371/journal.pone.0086872.g003
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Figure 4. Repression of PKM2 underlies miR-122-dependent phenotypes in vitro. (A) Protein (upper panel) and mRNA levels (lower panel)
of PKM2 in HepG2 or MHCC97H after transfection with siRNA targeted to PKM2 (siPKM2) or with siRNA control (siCtrl). (B) Lactate content of cells
after siPKM2 or siCtrl transfection. Data were derived from three independent experiments. (C) Protein (upper panel) and mRNA levels (lower panel)
miR-122 Affects HCC Metabolism through PKM2
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glycolysis observed in cancer cells into normal physiologic
metabolic pathways via promoting oxidative phosphorylation.
Increased glycolysis has an essential role in supporting HCC
development. HCC tumors appeared to have increased expression
of glycolytic genes, such as PKM2, hexokinase, LDHA, and GLUT-1,
and modulation of these genes could affect HCC cell growth
[16,17]. A recent report showed that HCC patients, whose tumor
had higher glucose uptake, had shorter survival times. In addition,
tumors with elevated Ki-67 labeling index (higher proliferation
rate) were accompanied with increased expression of glycolytic
genes [18]. Therapeutics targeting HCC metabolism is a relatively
unexplored area and should deserve more attention given the
evidences these years supporting its essential role in tumor
development.
PKM2 promotes aerobic glycolysis and tumorigenesis in many
tumor types, such as lung [13], prostate [19], and glioma [20]. The
gene is under a complex circuit of regulation: from transcriptional
[21] to post-transcriptional levels. Here, we showed PKM2
transcription is inhibited by miR-122. Other studies showed that
phosphorylation [16], acetylation [17], and oxidation [22] at the
post-transcriptional level also affect PKM2 expression and/or
function by modulating its enzyme activity or promoting protein
degradation (Fig 4E). Nevertheless, it is not clear to us, which one
of these regulatory mechanisms plays a central role in controlling
PKM2 contextually and temporally. The level of PKM2 needs to
be controlled at a precise level, and either higher or lower level of
PKM2 could inhibit tumorigenesis [23]. As such, both the
inhibitors and activators of PKM2 have been explored in pre-
clinical stage [24,25]. There are heated discussions on how to
target PKM2 in cancer metabolisms, and a deeper understanding
of the role of miR-122 in the complex regulatory circuits for the
metabolic pathway may lead to new approach in cancer
treatment.
In addition to PKM2, a cohort of metabolic genes is also under
the control of miR-122, and our data analysis revealed that miR-
122 is significantly correlated with a battery of glycolytic genes
(PKM2. ALDOA. GNPDA1 .PFKFB2 .AKR1B10). Further-
more, recent molecular profiling studies have shown genes affected
by miR-122 modulation are significantly enriched in metabolic
genes [2,6], suggesting that miR-122 may control several distinct
steps of metabolism. Indeed, animal models with modulated miR-
122 level revealed alteration in the metabolic phenotypes [3].
In conclusion, the present study demonstrated a regulatory role
of miR-122 in HCC metabolism, by targeting PKM2 (and likely
other glycolytic genes) that is involved in aerobic glycolysis
supporting cancer cells survival and proliferation. Many of the
HCC patients are often, and unfortunately, being excluded from
the surgical resection or chemotherapy because of their poor
underlying liver functions. Thus it is worth of investigating the due
diligence of miR-122 therapeutic functions – by improving the
liver function and by inhibiting cancer metabolisms, to benefit our
HCC patients.
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